Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2026
The role of c-MYC in gastric cancer prognosis: a Kaplan-Meier-derived patient data meta-analysis.
СтатьяМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moraes Francisco Cezar Aquino de, Tadeu Freitas Uchôa Matheus Gustavo, Tanimoto Larissa Emi, Girelli Cardoso Andressa, Hirata Mario Hiroyuki, Burbano Rommel Mario Rodríguez
Аннотация
BACKGROUND: Gastric cancer (GC) is the fifth leading cause of cancer-related death worldwide, with a median overall survival of approximately 12 months. The proto-oncogene c-MYC is among the most frequently activated oncogenes, implicated in roughly 20% of all malignancies.
METHODS: PubMed, Embase, and Web of Science were systematically searched for studies evaluating the association between c-MYC expression and (1) disease-specific survival (DSS) and (2) overall survival (OS). Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using a fixed-effects model. A two-sided p ≤ 0.05 was considered statistically significant.
RESULTS: Across 15 studies encompassing 2,372 gastric cancer patients (802 c-MYC-positive; 410 male), male gender was strongly associated with c-MYC positivity (OR 8.83; 95% CI 5.74-13.56; p < 0.00001), as were deeper invasion (T3-T4 vs T1-T2: OR 0.38; 95% CI 0.24-0.60; p < 0.00001) and advanced stage (III-IV vs I-II: OR 2.69; 95% CI 1.71-4.23; p < 0.00001). Patients with c-MYC-negative tumors exhibited a markedly higher DSS compared to those with c-MYC-positive tumors (HR 3.73; 95% CI, 2.22-6.26; p < 0.0001).
CONCLUSION: Our findings identify c-MYC as a significant prognostic biomarker for disease-specific survival in gastric cancer.
METHODS: PubMed, Embase, and Web of Science were systematically searched for studies evaluating the association between c-MYC expression and (1) disease-specific survival (DSS) and (2) overall survival (OS). Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using a fixed-effects model. A two-sided p ≤ 0.05 was considered statistically significant.
RESULTS: Across 15 studies encompassing 2,372 gastric cancer patients (802 c-MYC-positive; 410 male), male gender was strongly associated with c-MYC positivity (OR 8.83; 95% CI 5.74-13.56; p < 0.00001), as were deeper invasion (T3-T4 vs T1-T2: OR 0.38; 95% CI 0.24-0.60; p < 0.00001) and advanced stage (III-IV vs I-II: OR 2.69; 95% CI 1.71-4.23; p < 0.00001). Patients with c-MYC-negative tumors exhibited a markedly higher DSS compared to those with c-MYC-positive tumors (HR 3.73; 95% CI, 2.22-6.26; p < 0.0001).
CONCLUSION: Our findings identify c-MYC as a significant prognostic biomarker for disease-specific survival in gastric cancer.